Amendments To The Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

What is claimed is:

1. – 9. (Canceled).

10. (Currently Amended) A compound of formula (I) or a pharmaceutically acceptable salt thereof:



(I)

wherein:

R^1 represents $-C_{2-7}$ alkyl or $-(CH_2)_m-C_{3-7}$ cycloalkyl;

R^2 represents -X-C_{3-8} cycloalkyl, -X-aryl, -X-heteroaryl, -X-heterocyclyl, -X- C_{3-8} cycloalkyl-Y-C_{3-8} cycloalkyl, -X-C_{3-8} cycloalkyl-Y-aryl, -X-C_{3-8} cycloalkyl-Y-heteroaryl, -X-C_{3-8} cycloalkyl-Y-heterocyclyl, -X-aryl-Y-C_{3-8} cycloalkyl, -X-aryl-Y-aryl, -X-aryl-Y-heteroaryl, -X-aryl-Y-heterocyclyl, -X-heteroaryl-Y-C_{3-8} cycloalkyl, -X-heteroaryl-Y-aryl, -X-heteroaryl-Y-heteroaryl, -X-heteroaryl-Y-heterocyclyl, -X-heterocyclyl-Z-aryl, -X-heterocyclyl-Y-C_{3-8} cycloalkyl, -X-heterocyclyl-Y-heteroaryl or –X-heterocyclyl-W-heterocyclyl, such that R^2 is linked to O via a carbon atom;

W represents a bond, C_{1-6} alkyl, CO, COC_{2-6} alkenyl, O or SO_2;

X represents a bond or ~~methyl~~ C_{1-6}alkyl;

Y represents a bond, C_{1-6} alkyl, CO, COC_{2-6} alkenyl, O or SO_2;

Z represents a bond, CO, COC_{2-6} alkenyl, O or SO_2;

R^3 represents halogen, C_{1-6} alkyl, C_{1-6} alkoxy, cyano, amino or trifluoromethyl;

m represents an integer from 1-3;

n is 0, 1 or 2;

wherein said alkyl groups of R^1 may be optionally substituted by one or more substituents which may be the same or different and which are selected from the group consisting of halogen, cyano, C_{1-6} alkyl, C_{1-6} alkoxy, haloC_{1-6} alkyl and haloC_{1-6} alkoxy;

wherein said cycloalkyl, aryl, heteroaryl and heterocyclyl groups of R^2 may be optionally substituted by one or more substituents which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, cyano, nitro, =O, trifluoromethyl, trifluoromethoxy, fluoromethoxy, difluoromethoxy, C_{1-6} alkyl, pentafluoroethyl, C_{1-6} alkoxy, arylC_{1-6} alkoxy, C_{1-6} alkylthio, C_{1-6} alkoxyC_{1-6} alkyl, C_{3-7} cycloalkylC_{1-6} alkoxy, C_{1-6} alkanoyl, C_{1-6} alkoxycarbonyl, C_{1-6} alkylsulfonyl, C_{1-6} alkylsulfinyl, C_{1-6} alkylsulfonyloxy, C_{1-6} alkylsulfonylC_{1-6} alkyl, sulfonyl, arylsulfonyl, arylsulfonyloxy, arylsulfonylC_{1-6} alkyl, aryloxy, C_{1-6} alkylsulfonamido, C_{1-6} alkylamino, C_{1-6} alkylamido, -R^4, -CO_2R^4, -COR^4, C_{1-6} alkylsulfonamidoC_{1-6} alkyl, C_{1-6} alkylamidoC_{1-6} alkyl, arylsulfonamido, arylcarboxamido, arylsulfonamidoC_{1-6} alkyl, arylcarboxamidoC_{1-6} alkyl, aroyl, aroylC_{1-6} alkyl, arylC_{1-6} alkanoyl, or a group -NR^5R^6, –C_{1-6} alkyl-NR^5R^6, –C_{3-8} cycloalkyl-NR^5R^6, -$CONR^5R^6$, -NR^5COR^6, -$NR^5SO_2R^6$, -$OCONR^5R^6$, -$NR^5CO_2R^6$, -$NR^4CONR^5R^6$ and -$SO_2NR^5R^6$, wherein R^4, R^5 and R^6 independently represent hydrogen, C_{1-6} alkyl, -C_{3-8} cycloalkyl, -C_{1-6} alkyl-C_{3-8} cycloalkyl, aryl, heterocyclyl or heteroaryl or wherein-NR^5R^6 may represent a nitrogen containing heterocyclyl group, wherein said R^4, R^5 and R^6 groups may be optionally substituted by one or more substituents which may be the same or different, and which are selected from the group consisting of halogen, hydroxy, C_{1-6} alkyl, C_{1-6} alkoxy, cyano, amino, =O and trifluoromethyl~~;~~

~~or solvates thereof~~ with the proviso that a compound of formula (I) is not 3-cyclopropylmethyl-7-(1-isopropyl-piperidin-4-yloxy)-2,3,4,5-tettahydro-1H-benzo[*d*]azepine.

11. (Currently Amended) A compound as defined in claim 10 which is:

1-(5-{[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}-2-pyrazinyl)-2-pyrrolidinone;

3-(1-methylethyl)-7-[(phenylmethyl)oxy]-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

3-(2-methylpropyl)-7-[(phenylmethyl)oxy]-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

3-Ethyl-7-[(phenylmethyl)oxy]-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

3-(cyclopropylmethyl)-7-[(4-piperidinylmethyl)oxy]-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

4-{[4-({[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}methyl)-1-piperidinyl]carbonyl}benzonitrile;

3-(cyclopropylmethyl)-7-[({1-[(4-fluorophenyl)carbonyl]-4-piperidinyl}methyl)oxy]-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

7-({[1-(cyclopropylcarbonyl)-4-piperidinyl]methyl}oxy)-3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

3-(cyclopropylmethyl)-7-({[1-(tetrahydro-2*H*-pyran-4-ylcarbonyl)-4-piperidinyl]methyl}oxy)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

1-(6-{[3-(1-methylethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}-3-pyridinyl)-2-pyrrolidinone;

1-(6-{[3-(2-methylpropyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}-3-pyridinyl)-2-pyrrolidinone;

1-(6-{[3-(2,2-dimethylpropyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}-3-pyridinyl)-2-pyrrolidinone;

1-(6-{[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}-3-pyridinyl)-2-pyrrolidinone;

1-{6-[(3-ethyl-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl)oxy]-3-pyridinyl}-2-pyrrolidinone;

1-(6-{[3-(1-methylpropyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}-3-pyridinyl)-2-pyrrolidinone;

1-(6-{[3-(cyclobutylmethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}-3-pyridinyl)-2-pyrrolidinone;

3-(cyclopropylmethyl)-7-{[5-(3-methyl-1,2,4-oxadiazol-5-yl)-2-pyridinyl]oxy}-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

1-(4-{[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}phenyl)-3-methyl-2-imidazolidinone;

3-(cyclopropylmethyl)-7-[(phenylmethyl)oxy]-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

7-[(3-cyclohexylpropyl)oxy]-3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

3-(cyclopropylmethyl)-7-(phenyloxy)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

Ethyl 4-{[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}benzoate;

6-{[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}-*N*-methyl-3-pyridinecarboxamide;

5-{[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}-*N*-methyl-2-pyrazinecarboxamide;

1,1-dimethylethyl 4-{[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}-1-piperidinecarboxylate;

3-(cyclopropylmethyl)-7-(4-piperidinyloxy)-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

4-[(4-{[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}-1-piperidinyl)carbonyl]benzonitrile;

1-(5-{[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}-2-pyridinyl)-2-pyrrolidinone;

1-(5-{[3-(2-methylpropyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}-2-pyridinyl)-2-pyrrolidinone;

1-(5-{[3-(1-methylethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}-2-pyridinyl)-2-pyrrolidinone;

1,1-dimethylethyl 4-({[3-(cyclopropylmethyl)-2,3,4,5-tetrahydro-1*H*-3-benzazepin-7-yl]oxy}methyl)-1-piperidinecarboxylate;

3-(cyclopropylmethyl)-7-[(4-iodophenyl)oxy]-2,3,4,5-tetrahydro-1*H*-3-benzazepine;

or a pharmaceutically acceptable salt ~~or solvate~~ thereof.

12. (Previously Presented) A pharmaceutical composition which comprises the compound of claim 10 or a pharmaceutically acceptable salt ~~or solvate~~ thereof and a pharmaceutically acceptable carrier or excipient.

13. (Currently Amended) A method of treatment of neurological diseases which comprises administering to a ~~host~~ human in need thereof an effective amount of a compound claim 10 or a pharmaceutically acceptable salt ~~or solvate~~ thereof, wherein said neurological disease is selected Alzheimer's disease, age-related memory dysfunction, and mild cognitive impairment.

14. (Currently Amended) A process for the preparation of a compound of Claim 10 ~~formula (I)~~ or a pharmaceutically acceptable salt ~~or solvate~~ thereof, which process comprises:

(a) reacting a compound of formula (II)



(II)

wherein R^1, R^3 and n are as defined in claim 10, with a compound of formula $R^{2'}$-L^1, wherein $R^{2'}$ is as defined in claim 10 for R^2 or a group convertible thereto and L^1 represents a suitable leaving group ~~such as a halogen atom or an optionally activated hydroxyl group~~;

(b) reacting a compound of formula (III)



(III)

wherein R^2, R^3 and n are as defined in claim 10, with a compound of formula $R^{1'}$-L^2, wherein $R^{1'}$ is as defined in claim 10 for R^1 or a group convertible thereto and L^2 represents a suitable leaving group ~~such as a halogen atom~~; or

(c) reacting a compound of formula (III) as defined above, with a ketone of formula $R^{1''}$=O, wherein $R^{1''}$ is =C_{2-7} alkyl or =$(CH_2)_m$-C_{3-7} cycloalkyl or a group convertible thereto; or

(d) deprotecting a compound of formula (I) which is protected; or

(e) interconversion from one compound of formula (I) to another.